BANGALORE: Biocon announced on Tuesday that its licensing partner, Bentley Pharmaceuticals Inc., a specialty pharmaceutical company, has received approval from the Drug Controller General of India (DCGI) to proceed with Phase II clinical evaluation of `Nasulin', an intranasal insulin product, in Type II diabetic patients. As per the licensing agreement, Biocon is responsible for developing and marketing Nasulin in India and select territories.